Several studies have found higher rates of pCR in more aggressive tumors, such as human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancers (TNBC) [16,17,18,19,20]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.